At a glance
- Pentagastrin was approved by the FDA (Peptavlon, July 26, 1974), but the products are no longer marketed.
- PubMed lists 4,082 publications mentioning it, including 167 randomized controlled trials and 1,857 animal-only studies.
- ClinicalTrials.gov lists 7 registered studies testing it (0 active).
- FDA's adverse event system (FAERS) holds 1 report mentioning it; 1 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| NDA017048 | PEPTAVLON | Approved, discontinued | July 26, 1974 | WYETH AYERST |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Discovery of Promising USP21 Small Molecule Inhibitors: A Computational and Artificial Intelligence Modeling-Based Drug Repurposing Study for Non-Small Cell Lung Cancer.
- An Integrated Framework for Evaluating Poor Biorelevant Stability during First-in-Human (FIH) Development.
- Cocrystal mitigates the effects of elevated gastric pH on oral absorption of weakly basic drugs: a case study with ketoconazole-succinic acid cocrystal on beagle dogs.
- Gastrin for the treatment of acute graft-versus-host disease of the stomach.
- Calcitonin as Biomarker for the Medullary Thyroid Carcinoma.
- Pan-genome analysis and drug repurposing strategies for extensively drug-resistant Salmonella Typhi: Subtractive genomics and e-pharmacophore approaches.
- Prodrug Strategy to Address Impaired Oral Absorption of a Weakly Basic TYK2 Inhibitor Caused by a Gastric Acid-Reducing Agent.
- Diagnostic challenges in calcitonin negative medullary thyroid carcinoma: a systematic review of 101 cases.
- Rebound Acid Hypersecretion after Withdrawal of Long-Term Proton Pump Inhibitor (PPI) Treatment-Are PPIs Addictive?
- Polygalic acid inhibits african swine fever virus polymerase activity: findings from machine learning and in vitro testing.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 7
- Active
- 0
- With posted results
- 0
Conditions studied
| Study | Status | Phase | Start |
|---|---|---|---|
| A New Method for Determining Gastric Acid Output Using a Wireless Capsule | Completed | — | June 18, 2008 |
| An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) | Completed | Phase 4 | Sep 2002 |
| Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously | Completed | Phase 4 | Aug 2002 |
| Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv | Completed | Phase 4 | Jul 2002 |
| Effect of Repeated Doses of YF476 on Stomach Acidity | Completed | Phase 1 | Oct 2001 |
| Effect of Single Doses of YF476 on Stomach Acidity | Completed | Phase 1 | Oct 2001 |
| Diagnosis and Treatment of Pheochromocytoma | Completed | — | Oct 1988 |
All 7 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 1
- Serious
- 1
- With death outcome
- 0
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.